{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreieekt2mmcmqk6tvbp7oy7nritvamtv2fno6f6zxaemjgdqmcmthpi",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3ml5avhnfh262"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiagwgiclqcx3kfhnkkhhmh7yuzoyuldw7t4kfuraa5mxfzzurmlhu"
    },
    "mimeType": "image/jpeg",
    "size": 36285
  },
  "path": "/2026/05/05/cytokinetics-myqorzo-non-obstructive-hypertrophic-cardiomyopathy-trial/?utm_campaign=rss",
  "publishedAt": "2026-05-05T11:30:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "biotechnology",
    "cardiology",
    "drug development",
    "STAT+"
  ],
  "textContent": "A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost for sales.",
  "title": "STAT+: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease",
  "updatedAt": "2026-05-05T11:56:55.000Z"
}